spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  histone deacetylase 

 HSMN NewsFeed - 29 Nov 2021
Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for its All-Oral Combination of Nanatinostat and Valganciclovir (Nana-val) for the Treatment of Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Apr 2020
Viracta Receives Welcome FDA Guidance at Type C Meeting for the Treatment of EBV-Associated Lymphomas
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Nov 2019
Alkermes Completes Acquisition of Rodin Therapeutics
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 16 Apr 2019
Viracta Receives Orphan Drug Designation from the US FDA for its Lead Epigenetic Drug Candidate Nanatinostat for EBV-Associated Cancers
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Jun 2018
Proposed Remetinostat Phase III Design Results in Delay in Planned Start of Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Apr 2017
NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 3 Mar 2016
Huya Bioscience International Expands Senior Management Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 23 Jan 2016
Cellceutix Releases Data Used in Receiving FDA Orphan Drug Designation of Kevetrin for Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Nov 2015
Triphase Accelerator Corporation Announces FDA Orphan Drug Designation for Marizomib in Malignant Glioma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Aug 2015
Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2014
Curis Announces Executive Management Transition
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Apr 2014
MEI Pharma Adds Former VC David Urso as Senior Vice President of Corporate Development and General Counsel
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Mar 2014
William R. Ringo Joins Mirati Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Feb 2014
Spectrum Pharmaceuticals Announces FDA’s Acceptance of NDA Filing for Beleodaq(TM) (belinostat) for Injection, a novel pan-HDAC inhibitor
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Oct 2013
Syndax Names Steven M. Fruchtman, M.D., Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Aug 2013
Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 30 Jan 2013
MEI Pharma Announces Retirement Of Chairman Bryan Williams From Board Of Directors And Appointment Of Christine White As Lead Director
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Dec 2012
Spectrum Pharmaceuticals Announces Achievement of Primary Endpoint in Belinostat Registrational Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Nov 2012
Curis Announces Worldwide In-Licensing of IAP Inhibitor GDC-0917 From Genentech
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 22 May 2012
EnVivo Pharmaceuticals Appoints Alfred Sandrock, M.D., Ph.D., to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 19 Apr 2012
EnVivo Pharmaceuticals Names Christopher L. Burnley Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Apr 2012
TONIX Pharmaceuticals Strengthens Management Team with the Appointments of Its New Chief Financial Officer and Senior Director of Drug Development
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 24 May 2010
Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 15 Jan 2010
Celgene Completes Acquisition of Gloucester Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 8 Jan 2010
Acetylon Pharmaceuticals Tops Up Series A Financing with $2 Million Note And Appoints Simon Jones VP Biology and Preclinical Development and John van Duzer VP Chemistry and Manufacturing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 7 Dec 2009
Celgene to Acquire Gloucester Pharmaceuticals
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 9 Sep 2009
EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Sep 2009
FDA Advisory Committee Recommends Gloucester Pharmaceuticals' Romidepsin for Approval for Cutaneous T-cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Aug 2009
Acetylon Pharmaceuticals Raises $7.25 Million Series A to Develop Next-Generation Selective HDAC Inhibitors for Cancer and Rheumatoid Arthritis
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 5 Sep 2008
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Jun 2008
MethylGene Reports Clinical Data for MGCD0103 at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Apr 2008
CuraGen Sells Ownership of Belinostat to TopoTarget A/S
Biopharmaceuticals
 HSMN NewsFeed - 14 Feb 2008
MethylGene and Pharmion Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Feb 2008
Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Feb 2008
Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Feb 2008
MethylGene and Pharmion Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 28 Jan 2008
Gloucester Pharmaceuticals Announces New Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Dec 2007
Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Dec 2007
CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Nov 2007
Marketing Application for Vorinostat Filed in Europe for the Treatment of Advanced, Refractory Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Nov 2007
Celgene to Acquire Pharmion for $2.9 Billion in Cash and Stock
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 26 Sep 2007
EnVivo Pharmaceuticals Announces Executive Appointment
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Sep 2007
Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 21 Aug 2007
MethylGene and Pharmion Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Aug 2007
Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Aug 2007
FDA Grants Tikvah Therapeutics, Inc. Orphan Drug Status for Sodium Phenylbutyrate for the Treatment of Spinal Muscular Atrophy
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Jul 2007
Mersana Therapeutics, Inc. Appoints Pharmaceutical Industry Veteran Nicholas G. Bacopoulos, Ph.D. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jun 2007
Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Pharmion and MethylGene Report Preliminary Data for MGCD0103 at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 May 2007
Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Apr 2007
Syndax Pharmaceuticals Inc. Closes $40 Million Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 20 Feb 2007
Gloucester Pharmaceuticals Appoints Pharmaceutical Veteran, Donald Hayden, as Vice-Chairman
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jan 2007
Gloucester Pharmaceuticals Receives Special Protocol Assessment for Pivotal Phase II Trial of Romidepsin in Patients with Peripheral T-Cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Dec 2006
Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for Peripheral T-Cell Lymphoma at the 2006 American Society of Hematology (ASH) Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2006
Gloucester Pharmaceuticals Reports Clinically Significant Responses in Interim Analysis of Pivotal Trial for Cutaneous T-Cell Lymphoma at the 2006 American Society of Hematology (ASH) Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Nov 2006
Kalypsys Raises $100 Million in a Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 16 Nov 2006
CuraGen and TopoTarget Announce Initiation of NCI-sponsored Phase II Clinical Trial of PXD101 for Myelodysplastic Syndrome
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Oct 2006
S*BIO Appoints Joy Zhu Senior Vice President of Global Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Oct 2006
FDA Approves ZOLINZA(TM) (Vorinostat) for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-Cell Lymphoma Who Have Tried and Failed Other Therapies
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Oct 2006
FDA Approves ZOLINZA(TM) (Vorinostat) for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-Cell Lymphoma Who Have Tried and Failed Other Therapies
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Jun 2006
Gloucester Pharmaceuticals Appoints Jean C. Nichols, Ph.D., Executive Vice President and Chief Scientific Officer
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 25

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 25 additional stories matching:
histone deacetylase
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.